Horizon Scanning: weekly taspoglutide vs. twice daily exenatide for type 2 diabetes
This study, published in Diabetes Care, compared the efficacy and safety of once-weekly taspoglutide with twice-daily exenatide.
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomised to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 micrograms twice daily (n = 392) in an open-label, multicentre trial. The primary end point was change in HbA1c after 24 weeks.
The authors reported the following results:
. Both doses of taspoglutide reduced HbA1c significantly more than exenatide (taspoglutide 10 mg: -1.24% [SE 0.09], difference -0.26, 95% CI -0.37 to -0.15, P < 0.0001; taspoglutide 20 mg: -1.31% [0.08], difference -0.33, -0.44 to -0.22, P < 0.0001; exenatide: -0.98% [0.08])
. Both taspoglutide doses reduced ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news
More News: Byetta | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Fortamet | Metformin | Obesity | PET Scan | Study